ReviewInternational journal of preventive medicine2025
Non-Invasive Prenatal Testing (NIPT): A Paradigm Shift in Prenatal Care.
Review in International journal of preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Analysis of diagnostic consistency rate and pregnancy outcomes in pregnant women with high-risk NIPT undergoing transabdominal amniocentesis.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prenatal screening has undergone a profound transformation with the emergence of Non-Invasive Prenatal Testing (NIPT), a technology that analyzes cell-free fetal DNA (cffDNA) in maternal blood to detect common chromosomal abnormalities. Compared to traditional biochemical and ultrasound-based screening, NIPT offers markedly higher accuracy, earlier detection, and reduced procedural risk, representing a true paradigm shift in prenatal care. This narrative review synthesizes current evidence on the clinical performance, technological evolution, and ethical implications of NIPT within modern obstetric practice. Findings indicate that NIPT demonstrates exceptional sensitivity and specificity for trisomy 21, with strong performance for trisomy's 18 and 13 and promising application to sex chromosome aneuploidies. Its adoption has led to a significant reduction in invasive diagnostic procedures such as amniocentesis, thereby enhancing maternal safety and psychological comfort. Recent advancements-including SNP-based and fragmentomics-enhanced sequencing, artificial intelligence integration, and combined screening approaches-have further expanded NIPT's precision and potential scope. However, challenges persist regarding test accessibility, cost-effectiveness, and the interpretation of complex results from expanded panels. Beyond its clinical and technological merits, the review underscores the importance of addressing ethical, legal, and social concerns such as informed consent, privacy protection, and equitable access, particularly as direct-to-consumer models emerge. Ultimately, NIPT stands as a transformative innovation in reproductive medicine, offering a safer and more individualized approach to prenatal screening. Its continued success will depend on the establishment of robust ethical frameworks and equitable implementation strategies to ensure that advances in genetic technology translate into meaningful and responsible improvements in maternal-fetal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.